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Since the seventeenth century, the ability to 
reproduce research findings has been the 
acid test by which scientists distinguish facts 
from mere anecdotes1. Reproducibility — 
defined here as the ability to produce similar 
results by independent replicate studies — is 
thus a cornerstone of the scientific method. 
Recent investigations, however, have shown 
that the reproducibility of research findings 
is poor across virtually all disciplines of 
research2–9. It is crucial to identify the causes 
of poor reproducibility and implement 
effective strategies for improvement for 
scientific, economic and ethical reasons.
The reproducibility of preclinical 
research involving animal models is deemed 
to be especially poor10. More than half 
of the published findings in this area are 
considered irreproducible, representing a 
cost of US$28 billion per year in the USA 
alone11. Additional resources are used on 
often fruitless follow- up studies, which 
in turn generate opportunity costs by 
preventing researchers from following more 
promising research avenues or leading to 
time lost in scientific dead ends. These 
economic and scientific costs are associated 
with significant ethical issues. In biomedical 
Biological variation
Sources of biological variation. Variation 
is ubiquitous in nature, and even casual 
observations reveal that individual 
organisms differ in numerous phenotypic 
traits. Such phenotypic variation reflects 
the combined effects of the organisms’ 
genotypes and their responses to the 
environment, integrated over their 
lifetimes13–16. Phenotypic variation covers 
all levels of organization from molecular 
mechanisms to behaviour. There are many 
biological causes of phenotypic variation 
besides genetic differences, including 
developmental stage or age, early experience 
and social status. Variation owing to the 
environment is complex and varies with 
time, spatial scale (for example, climate) 
and the nature of environmental factors 
(for example, food, predators, mates and 
environmental toxins). The norm of reaction 
describes the relationship between one 
or more environmental factors and the 
phenotype for a given genotype17,18, and 
such norms of reaction may differ among 
genotypes (Box 1). Thus, it is not uncommon 
for different genotypes to respond differently 
to environmental factors19. The effects of 
environmental factors accumulated over 
a lifetime may not be easily detectable by 
morphological, physiological or behavioural 
analysis, although they may leave a unique 
fingerprint on gene and protein expression 
levels, thereby contributing to the fine- 
tuning of the phenotype20. Recent advances 
in the study of epigenetics have added a 
layer of complexity to our understanding 
of the interactions between genotype 
and environment in the expression of 
phenotypic plasticity21,22.
In experimental animal research, the 
effect of a treatment is typically measured 
at the level of the phenotype. It can be 
thought of as the plastic response of some 
phenotype (the animal model) to the 
experimental treatment. Without plasticity 
in response to a treatment (for example, 
the administration of a drug or a genetic 
manipulation), there would be no treatment 
effect (that is, an effect size of zero). 
However, the direction and magnitude 
of a treatment effect depend not only on 
the nature, duration and intensity of the 
treatment but also on the animal’s current 
phenotype and the experimental context23,24. 
research, poor reproducibility not only 
attenuates medical progress but also harms 
animals subjected to inconclusive studies 
and potentially puts patients who are 
enrolled in clinical trials at risk.
Current discussions about the causes  
of poor reproducibility in animal research  
focus mainly on violations of good research 
practice, including a lack of scientific rigour, 
low statistical power, analytical flexibility 
(for example, P- hacking) and publication 
bias2,5,12. In this Perspective, we argue that, 
besides violations of good research practice, 
a major cause of poor reproducibility in 
animal research is a persistent disregard 
for the nature of biological variation in 
study design. We explain where biological 
variation comes from, how it differs from 
random noise and why it causes issues with 
reproducibility. We then discuss why current 
research practice is inadequate for dealing 
with biological variation and call for a 
paradigm shift in experimental design to 
improve reproducibility in animal research. 
Specifically, we propose diversification 
of study subjects through deliberate 
heterogenization of environmental factors  
as a measure of good experimental design.
Reproducibility of animal research  
in light of biological variation
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Abstract | Context- dependent biological variation presents a unique challenge to 
the reproducibility of results in experimental animal research, because organisms’ 
responses to experimental treatments can vary with both genotype and 
environmental conditions. In March 2019, experts in animal biology, experimental 
design and statistics convened in Blonay, Switzerland, to discuss strategies 
addressing this challenge. In contrast to the current gold standard of rigorous 
standardization in experimental animal research, we recommend the use of 
systematic heterogenization of study samples and conditions by actively 
incorporating biological variation into study design through diversifying study 
samples and conditions. Here we provide the scientific rationale for this approach 
in the hope that researchers, regulators, funders and editors can embrace this 
paradigm shift. We also present a road map towards better practices in view of 
improving the reproducibility of animal research.
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As phenotypes are complex and influenced 
by many interacting factors, the effect of 
the independent variable (for example, the 
experimental treatment) on an outcome 
variable (the dependent variable) is also 
context dependent. Thus, experimental 
results vary with both the internal state 
of animals (determined by genotype and 
experiences throughout development) 
and the external environmental factors (the 
environment in which the experiment is 
conducted). Environmental factors may 
interact additively or synergistically with the 
internal state of the animals, shaping their 
responses to the experimental treatment in 
specific ways (Fig. 1).
Biological variation and current best 
practice. In laboratory animal research, 
current best practice for dealing with 
biological variation is strict standardization of 
both the animals and their environment25–27. 
Standardization in animal experimentation 
has been described as “the defining of the 
properties of any given animal (or animal 
population) and its environment, together 
with the subsequent task of keeping the 
properties constant”25. It is intended, first, 
to reduce within- experiment variability so 
as to increase statistical power and, second, 
to reduce between- experiment variability 
so as to “increase the reproducibility of 
group mean results from one experiment 
to another”, thereby “improv[ing] 
comparability of results within and 
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Box 1 | Genetic variation, plasticity and norms of reaction
Phenotypic variation among and within individuals 
typically reflects the combined effects of genetic 
differences and environmentally induced 
variation13–16. When there is no plasticity (that  
is, the norms of reaction are flat), phenotypic 
differences among genotypes are robust across 
environmental conditions (see the figure, part a;  
the blue, purple and red lines in parts a–c represent 
distinct genotypes). However, the relative 
importance of environmentally induced phenotypic 
variation is highly context dependent and typically 
varies among populations, traits and genotypes. 
When the norms of reaction for different genotypes 
have parallel positive or negative slopes (see the 
figure, part b), the plastic responses induced by  
the environment are shared and phenotypic 
distributions reflect the combined effects of 
genetic and environmental variation. The sensitivity 
or responsiveness of phenotypic expression can 
vary among environmental components. A given 
phenotypic trait may show a plastic response to 
some environmental factors while being insensitive 
to others. Similarly, a given environmental factor 
may induce a plastic response in some phenotypic 
trait or traits, while the development of other traits 
may be robust and independent of the same  
factor. The phenotypic response induced by an 
environ mental factor can also be genotype specific, 
in which case the phenotypic variation in a 
population depends on the joint effects of genetic 
variation, phenotypic plasticity and genetic variation 
in plasticity. When the reaction norms vary among 
genotypes, there is genetic variation in plasticity 
(that is, gene × environment interactions (G×e)), 
meaning that the plastic response induced by the 
environmental factor varies according to genotype 
(see the figure, part c).
The norm of reaction describes, for a specific 
genotype, how the distribution of an environmental factor is translated 
into a phenotypic distribution. This means that even in genetically 
homogeneous populations, such as inbred laboratory strains, the patterns 
of phenotypic variation can vary depending on the environment. 
A con­tinuous,­normally­distributed­environmental­variation­can­generate,­
for example, a continuous, skewed phenotype distribution (see the figure, 
part d). However, for threshold traits with a step- shaped reaction norm, 
continuous environmental distributions can also generate discrete 
(categorical) or bimodal phenotypic trait distributions for a single 
genotype (see the figure, part e). Here the expression of a phenotypic trait 
changes from one state to another at some critical level, dosage, intensity 
or concentration in the environment. The critical level that induces the 
phenotypic shift from one state to another (for example, response or no 
response) may vary among genotypes. In other cases, bimodal or 
multimodal trait distributions may manifest themselves in populations that 
comprise different genotypes, regardless of whether they show or do not 
show plasticity (see the figure, part f). Furthermore, a given phenotypic 
trait may display a discrete or bimodal frequency distribution if the 
genotype or genetically homogeneous strain is exposed to a discrete or 
bimodally distributed environment (see the figure, part g). A practical 
implication of such context- dependent responsiveness is that the 
phenotypic responses induced by a specific experimental treatment (for 
example, intervention studies designed to evaluate drug responsiveness) 
may vary between trials conducted in different laboratories. The 
importance and consequences of developmental plasticity, phenotypic 
flexibility and genotype–environment interactions are well established  
in quantitative genetics and evolutionary ecology, and can explain why 
different studies may generate conflicting outcomes.
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the properties” does not necessarily imply 
identical environmental conditions for all 
animals of a study population, and other 
definitions of standardization exist that 
refer to “the setting of, and compliance with, 
standards” rather than making everything 
the same (for example, see ReF.28). However, 
in laboratory animal experimentation, 
standardization is generally equated with 
such homogenization29–32, and throughout 
this article the term ‘standardization’ refers 
to the homogenization of study populations. 
As a result, standardization renders animals 
within experiments more homogenous and 
thus less variable. Reduced variation in the 
results increases statistical power and allows 
a reduction of sample size (to detect a given 
effect size). Therefore, standardization has 
been advocated also for ethical reasons as a 
means of reducing animal use as required 
by the 3Rs principles (replace, reduce, 
refine)31,33–36.
There are two main problems with this 
conception of standardization as applied 
to laboratory animal research. It is based 
on the confusion of biological variation 
with extraneous noise and on the myth of a 
pure treatment effect that ‘emerges’ as more 
sources of variation are eliminated. Whereas 
standardization can be an effective means 
to reduce extraneous noise (for example, 
measurement error and undesirable 
environmental effects), it fails to address 
biological variation. Since variation is a 
fundamental property of any population 
of organisms, treatment effects can be 
assessed and interpreted meaningfully only 
against biological variation — including 
gene × environment interactions. Owing to 
context- dependent variability in responses 
to treatment (Box 1), there is no such thing 
as a pure treatment effect for a population of 
living organisms. Any definition of a target 
population, therefore, needs to consider 
the range of genotypic and environmental 
variation for which the inferences of a study 
should be valid (the inference space). Studies 
that are too narrowly defined cannot reliably 
be generalized: if only males are included, 
the results may differ in meaningful ways in 
females37,38; the responses of a single inbred 
strain may not hold for other strains39,40; 
and mice housed in isolation might respond 
differently to certain drug treatments than 
individuals housed in groups41. Although 
extension of the inference space has been 
discussed specifically with regard to genetic 
variation and the inclusion of both sexes 
in preclinical animal studies (Box 2, Box 3), 
here we argue that this discussion should be 
extended to diversification of environmental 
conditions.
Outcomes, both the main effects of 
treatments and treatment × environment 
interactions, that are stable under large 
biological variation are considered to be 
robust42 and may be characterized by the same 
flat norm of reaction for all genotypes and 
all variants of environmental factors (Box 1; 
Fig. 1). However, such cases of universal 
robustness are probably rare exceptions 
rather than the rule. In most cases, treatment 
effects will vary depending on a set of both 
genetic and environmental factors. Such 
modulating effects can be highly specific 
and unexpected. For example, a change 
from open cages to individually ventilated 
cages altered outcomes in a mouse model 
of infection- mediated neurodevelopmental 
disorders43, the behavioural sensitivity of 
wild- type mice44,45 and the behavioural 
phenotype of a validated mutant neuregulin 1 
mouse model for schizophrenia46 but not the 
behavioural phenotypes of three commonly 
used inbred mouse strains47. Knowledge of 
context- dependent variation of treatment 
effects is a crucial aspect of scientific evidence. 
It is necessary for identifying the target 
population, as well as the conditions under 
which a finding is likely to be reproducible24. 
It is also key for translational research and the 
very basis of precision medicine23,48–50.
Reproducibility and the standardization 
fallacy. Reproducibility is assessed by 
comparing the results of independent 
replicate studies12,51. The conditions of any 
two studies are never exactly the same, even 
when researchers go to great lengths to 
harmonize the characteristics of animals, 
housing conditions, experimental protocols 
and test conditions24,51–53. Differences are 
unavoidable since the animals, the personnel 
interacting with the animals, the animals’ 
microbiome and many other factors resist 
standardization39,54–60. Different laboratories, 
therefore, inevitably standardize these 
variables to different local study contexts, 
producing increasingly distinct study 
populations as standardization gets more 
rigorous. With every additional variable 
that is standardized, one risks that the 
inference space of a study (and with it the 
external validity of its results) decreases29,61,62. 
This misguided attempt to enhance 
reproducibility at the expense of external 
validity is referred to as the ’standardization 
fallacy’63. Although direct evidence for the 
standardization fallacy is currently limited 
to simulations across replicate studies29,62,64 
and only a few dedicated experimental 
studies65,66, there is indirect evidence 
showing, for example, that the experimenter 
or the laboratory may account for most 
Environmental condition Environmental condition Environmental condition
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Δ = T – C
Fig. 1 | Context-dependent treatment effect. a | Phenotypic values measured in treatment and con-
trol animals can be robust, which means they are insensitive to changes in the environmental condition. 
b | In this case, the response to the treatment — that is, the treatment effect (double- headed arrows) 
— is also robust. c,d | If phenotypic values are sensitive to environmental conditions, the response can 
still be robust if the environmental effect is purely additive. e,f | However, a response to a treatment 
can be context dependent if there is an interaction between the treatment and the environment.
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of the variation in outcome measures 
across replicate studies within or between 
laboratories, respectively23,52.
Results can be reproduced successfully 
only if they are robust against the variation 
that exists between independent replicate 
studies. It is therefore not surprising that 
standardization has invariably been found 
to be a cause of, rather than a cure for, 
poor reproducibility65–68 (but see ReFs69,70 
for a critical analysis of ReF.66). Eliminating 
biological variation through the use of 
standardization to narrow the inference 
space of a specific animal phenotype 
may, therefore, be a highly inefficient 
strategy for generating scientific evidence. 
It is akin to the atomization of animal 
research by investigating each specific 
gene × environment interaction in a 
separate experiment, thereby minimizing 
the information gain per experiment to 
virtually zero. The detection of robust 
and reproducible effects of interventions 
would thus require a very large number 
of independent replicate studies and 
rely entirely on meta- analysis. The other 
extreme, however, is not an efficient strategy 
either. Incorporating the full range of both 
genetic and environmental variation into the 
design of every experiment would render 
experiments unmanageable. A key challenge 
for future research is thus to find the right 
balance between biological complexity and 
experimental tractability. The following 
section presents approaches to account for 
biological variation in view of the limitations 
set by these two extremes.
Call for a paradigm shift
In contrast to the current practice of 
dogmatic standardization, we advocate 
systematic heterogenization of animal 
subjects by deliberately incorporating 
known sources of biological variation in 
study designs. Heterogenization may be 
based on controlled variation, for instance 
by systematically varying the genotype 
(for example, both sexes or several inbred 
strains), the state and history of the 
individual (for example, different housing 
conditions or different age classes), or 
the test condition (for example, different 
test times or alternative test systems). 
Alternatively, heterogenization may be based 
on uncontrolled variation, for example by 
using outbred study populations, by splitting 
experiments into multiple independent 
batches of animals or by conducting 
multilaboratory studies. These different 
types of heterogenization, as well as rigorous 
standardization, have their place in research, 
as outlined in more detail next.
Study designs and analysis plans. Study 
design is often taught as if each experiment 
were a fully independent and conclusive 
study. However, most experiments are 
part of research programmes including 
a series of experiments, each providing 
incremental gains of knowledge that guide 
the next steps in the programme71,72. Ideally, 
research into new and unexplored areas 
begins with exploratory studies that can 
be used to generate and select hypotheses 
worthy of further investigation73,74. 
Such hypotheses may then be tested in 
confirmatory studies to establish proof of 
concept, followed by studies assessing the 
generalizability of the findings. However, 
often there is no clear distinction between 
exploratory and confirmatory studies49.  
This can cause problems as different types  
of study and different stages of research  
require different study designs, sample  
sizes, analysis plans and interpretation  
of outcomes.
Initial exploratory studies tend to be 
small, limited to a single strain of animals 
and often only of one sex (predominantly 
males in animal experiments75–77), and they 
are usually conducted under rigorously 
standardized conditions. Given their aim 
to generate new hypotheses or identify 
Box 2 | Heterogenization in animal research
Genetic heterogenization
Soon after the creation of inbred strains of rodents, researchers began to debate the advantages 
and disadvantages of their use as models for human medical conditions. Proponents for the use of 
inbred strains mainly emphasize the advantage of working with a genetically well- defined and 
standardized model35,87,98. A stringent breeding regime over 20 or more generations will lead to an 
inbreeding coefficient larger than 0.99 and homozygosity in more than 98% of all loci99, making 
animals­of­one­strain­from­one­breeding­line­almost­genetically­identical­(although­a­few­de novo­
mutations, tandem repeats and transposon insertions always add marginal variability16). It has been 
noted that reliance on a single genotype can be risky as a sample of a single inbred strain will not 
reflect the genetic diversity of natural populations to which the insights should be applied in the 
end100. Furthermore, homozygosity as a result of inbreeding might render inbred mice poor models 
for outbred populations of heterozygous organisms. Five different approaches for genetic 
diversification within an experiment have been suggested: use of outbred strains100, use of F1 
hybrids101, use of diversity outbred strains102, use of multiple inbred strains35 and use of both 
sexes79,103,104. The choice of the heterogenization strategy will depend on whether one aims 
exclusively for variation within individuals (that is, re- establishing heterozygosity through 
hybridization), variation between subgroups of individuals (use of both sexes or multiple strains)  
or variation between individuals (use of outbred strains).
Given the genetic uniformity of inbred strains, one might expect to find less between- animal 
variation of phenotypes in inbred strains than in stocks of outbred or wild- derived mice. The 
empirical evidence for this assertion is mixed, and some empirical studies105,106 and a recent 
meta- analysis of 241 data sets107 report no overall difference in phenotype variability between 
inbred and outbred strains. Furthermore, groups of inbred mice kept under the same standardized 
conditions show sometimes surprisingly large phenotypic variation40. The reasons for high 
variability in inbred strains are poorly understood, although it was suggested that heterozygosity 
might have stabilizing effects, buffering the development and ensuring robust phenotypes.  
The loss of heterozygosity due to inbreeding might then disrupt these buffering mechanisms, 
leading to unstable phenotypes highly susceptible to fluctuations of the internal and external 
milieu40,107–109.
Other targets for heterogenization
Age affects many physiological and behavioural processes110–112 and has been suggested as a 
feasible factor for heterogenization53,65,79,83. In addition to age, reproductive experience has been 
shown to influence diverse physiological parameters and epigenetic marks113–116. Furthermore, 
seasonal changes, differences in the light regime and differences in the timing of experiments have 
been shown to affect study outcomes52,68,117,118. These environmental factors could be considered as 
further heterogenization factors. An experimental study showed that co- housing laboratory mice 
with feral and pet store mice profoundly affected the immune system of the mice, instigating 
memory­T cell­differentiation­and­leading­to­substantial­differences­in­immune­responses­to­
bacterial infection119. Heterogenizing the microbial environment of laboratory mice was suggested 
as a tool for producing models with immune responses resembling those of adult humans more 
closely. only a few studies have used different housing conditions for heterogenization, such as 
cage size or environmental enrichment65,66, possibly because this is logistically more demanding. 
However, an earlier study found that memory deficits in mice deficient in hippocampal NmDA- 
type glutamate receptors were overcome by environmental enrichment, possibly as a result of 
enrichment- induced NmDA receptor- independent synaptogenesis120. In this case, systematic 
variation of environmental complexity facilitated the detection of a biologically relevant gene × 
environment interaction.
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hypotheses worthy of further investigation, 
this is a highly inefficient strategy, more 
likely to generate ‘findings’ that are context 
specific. Exploratory studies based on 
carefully heterogenized designs, however, 
may provide considerable knowledge 
of how the effect of the experimental 
intervention (the effect size) is modified by 
the heterogeneous features (including both 
genetic and environmental factors) being 
incorporated in the experimental design. 
Knowing whether effect sizes are likely to 
be robust or context dependent permits a 
much more targeted approach to follow- up 
studies testing for proof of concept and 
generalizability49.
There are various ways to heterogenize 
a study population. For example, we 
may want to estimate an average effect 
without exploring the impact of each 
heterogenization factor (for example, strain 
or environmental condition). In this case, 
we may split the study sample into groups 
or ‘blocks’, using a randomized complete 
block78 design (Box 4). This usually does 
not require increase of the sample size 
compared with a completely standardized 
study design to achieve the same power79. 
In many cases, there is already a blocking 
factor present in the study design, for 
example to account for batch, cage or pen 
effects. In such cases, heterogenization 
may be achieved by deliberately adding 
additional heterogeneity between blocks, 
which improves external validity without 
sacrificing the internal validity achieved by 
within- block standardization. Such block 
heterogenization is suitable to determine 
whether a treatment effect is robust over a 
range of conditions, in which case it is also 
more likely to be reproducible across studies 
than an effect that interacts strongly with a 
blocking factor.
Sometimes we are interested in 
identifying the sources of biological 
variation modulating the response to the 
treatment and assessing the magnitude 
of the influences of specific factors (for 
example, sex, age or specific environmental 
parameters) rather than just maximizing 
external validity. In such cases, these 
factors need to be included as fixed 
effects (differences in the means owing to 
the influence of independent variables) 
in the experimental design and analysis. 
The inclusion of fixed effects as factors 
in the study design, especially if they are 
varied across multiple factor levels (that 
is, values), may require larger sample sizes 
than standardization or heterogenization 
using a random blocking factor (a factor 
increasing variability). Therefore, this should 
be considered for cases only where the 
estimation of these effects is scientifically 
warranted, for example to assess the effects 
of sex — which we generally recommend 
— or other relevant biological variables (for 
example, specific co- morbidities in animal 
models of diseases) on the outcome variable.
Heterogenized study designs, which 
incorporate biological variables either as 
random or fixed effects, should become 
the default option for almost all study 
types of experimental animal research — 
including exploratory studies. Rigorous 
standardization of study animals to a single 
genotype and a single sex and to being kept 
under one specific environmental condition 
can be justified only on the grounds that 
either the outcome of interest was previously 
shown to be robust against variation in these 
factors (albeit absence of evidence should 
not be mistaken for evidence of absence) 
or the research question is truly limited to 
that specific context (for example, as in the 
study of sex- specific diseases). In all other 
cases, systematic heterogenization will be 
scientifically more valid and — especially 
when considering single studies as parts of 
a larger research programme — will also 
be economically beneficial and ethically 
preferable.
Scientific, economic and ethical implications. 
To assess the scientific, economic and 
ethical implications of heterogenization, it is 
important to take a perspective that extends 
beyond the individual experiment80. By 
reduction of within- experiment variation, 
standardization can increase test sensitivity 
for a specific standardized study context, 
which in turn allows reduction of the sample 
size as required by the 3Rs principles34. 
However, as standardization produces results 
with a validity that may be limited to that 
specific context, it generates a greater need 
for follow- up studies, thus requiring the use 
of additional animals. If we seek to minimize 
the use of animals to achieve our research 
goals, we should focus on maximizing the 
amount of knowledge gain per animal  
and/or per study rather than minimizing the 
number of animals per study. The scenarios 
presented above demonstrate how scientific 
evidence can be generated more efficiently 
and, as a consequence, more ethically if 
Box 3 | Inclusion of both sexes
About three decades ago, an imbalance in clinical research, with female participants being 
under- represented, led to a series of policy changes to encourage or enforce the inclusion of 
women in medical studies121,122. Although those initiatives were originally restricted to late- phase 
(phase III) clinical studies, more recently the uS National Institutes of Health, the Canadian 
Institutes of Health Research and the european Commission extended their recommendation for 
the inclusion of both sexes to preclinical animal studies77,123,124. Sex- based differences in basic 
biological function, disease processes and treatment responses have been found in many animal 
models79,125–132. There are marked differences in global gene expression patterns between male and 
female animals. In mice, the majority (50–75%) of genes have been shown to be sex- biased (that is, 
expressed at different levels in the two sexes) even in non- reproductive tissues such as liver, fat, 
muscle and brain133. Cell- culture studies have demonstrated that neurons from male and female 
mice respond differently to various stimuli. Neurons from male mice were more sensitive to stress 
from reactive oxygen species and excitatory neurotransmitter, whereas neurons from female mice 
were more sensitive to some stimuli that prompt apoptosis38,134. These differences could have 
potential implications in treatments for stroke, traumatic brain injury, cerebral ischaemia and other 
neurological and psychiatric conditions, such as Parkinson disease and schizophrenia. Apart from 
sex differences likely stemming from differences in X and y chromosomal genes, sex- specific 
responses can also be mediated through hormones acting directly on genes throughout the 
genome125,133. As a consequence, researchers have started to diversify their study samples by 
including female animals, although parity has not been reached and specifically in neuroscience 
males are still predominant75,76.
one of the most common concerns regarding inclusion of female animals in research is the fear 
that this will require larger sample sizes. This would increase not only the costs but also the 
workload for research and, consequently, slow scientific progress135–137. Furthermore, owing to 
hormonal fluctuations across the reproductive cycle, female animals are believed to be more 
variable and therefore their use would inherently require larger sample sizes. However, recent 
meta- analyses that examined variability among male and female mice41 and rats138 showed that 
males were equally or even more variable in all measured parameters. Whether inclusion of both 
sexes requires a substantial increase in the sample size depends on the specific aim of the study.  
If separate subgroup analyses for the sexes are planned, a balanced factorial design can ensure 
that the sample size need not be doubled but that a moderate increase of the required sample size 
will suffice103,104. otherwise, if sex is added merely as a heterogenization factor without the aim to 
test for sex- specific effects, then this does not require a larger sample size (or only a minimally 
larger sample size) than in a single- sex experiment79.
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biological variation is accounted for in the 
study design from very early on81,82. It is 
time to update the textbooks of laboratory 
animal science and establish systematic 
heterogenization of study populations 
as a new standard. As this implies a true 
paradigm shift, change management towards 
better practice is needed.
The path to implementation. Gene × 
environ ment interactions, phenotypic  
plasticity and reaction norms are funda-
mental biological concepts and standard 
knowledge taught in undergraduate genetics 
and biology classes (Box 1). The same applies 
to block experimental designs to incorpo-
rate and control for heterogeneity when  
one is studying the effect of one or more 
independent factors on an outcome  
variable (Box 4). Moreover, the limitations  
of standardization for external validity  
and reproducibility of results from animal 
experiments have long been known53,61,63,83. 
Why then do laboratory animal scientists 
persist in promoting a principle of experi-
mental design — rigorous standardization 
— that is incompatible with these insights? 
Answering this question requires a con-
sideration of the forces encouraging  
change and the resisting forces that hinder 
researchers from embracing biological  
variation as part of their experimental  
paradigms and thus maintain the status  
quo (standardization).
Box 5 lists forces impacting researchers’ 
engagement with changing practice. 
Understanding these forces and considering 
the interplay highlights that resisting forces 
dominate, which explains the challenge for 
our community to achieve the paradigm 
shift that is needed. A closer look at these 
factors will highlight how we can unfreeze 
the status quo by strengthening the driving 
forces and weakening the resisting forces, 
allowing the paradigm shift to occur84.
Exploring resisting forces and potential 
solutions. Our current research culture is 
made up of the beliefs, values and norms 
of behaviour (protocols and systems) of 
the community of researchers. A central 
belief determining current research practice 
is the conviction that standardization is a 
universal means to improve the validity of 
animal experiments and meet our ethical 
obligations to use as few animals as possible. 
As we have outlined already, this assertion 
does not hold if standardization is removing 
relevant biological variation. Although 
this problem was identified previously, 
Box 4 | Blocking design and heterogenization
Blocking is an effective means of exploiting the benefits of both 
standardization and heterogenization. Within blocks of subjects, the 
experimental conditions can be standardized as rigorously as possible  
(for example, use of same genotype, same age and same experimental 
context), so that any differences in response to the experimental treatments 
will most likely be attributable to the treatment. However, the blocks 
themselves can be heterogeneous and vary in one or several aspects.  
In the classic randomized complete block (RCB) design experiment,  
each treatment is assigned randomly to a single animal within each block 
(see the figure, part a). Such data can be analysed by a paired t test between 
treatment and control that are paired within blocks (B1 to B6) when there 
are only two treatments (treatment (T) and control (C) in part a of the 
figure), or in a linear (mixed- effect) model where block is treated as a 
fixed or­random­effect­when­there­are­more­treatments.­The­latter­models­
have the advantage of being adaptable to more complex experimental 
designs; for example, blocks of time that are nested within blocks of 
laboratories.
The strength of the RCB design is that the treatment effect can be 
estimated within each block, and therefore it is independent of the 
block- to- block heterogeneity. Hence, any context- general treatment 
effect will be unaffected by heterogeneity among blocks. moreover, the 
same design can be used to explore context dependencies. We can include 
fixed effects that describe differences among blocks and their effects can 
be estimated. We can, therefore, determine treatment effects that are 
consistent across blocks (and hence are likely to be generalizable to more 
heterogeneous settings) as well as those that differ among blocks.
one problem with the classic RCB design is that treatments that have a 
consistent effect in only a subset of the blocks may not be identified if the 
estimated effects are highly variable between the remaining blocks. This 
can be mitigated in two ways. If there is prior knowledge of the sources of 
context dependencies, heterogeneity across candidate contexts can be 
built into the experiment. This can be analysed by fitting additional fixed 
effects for these factors using a split plot design where these factors are 
whole plot factors. If there is no prior knowledge of context dependencies, 
these can be explored and mitigated by replication within blocks (for 
example, B1 and B2 in part b of the figure), thus yielding a measure of 
within block variability which can be used to assess whether treatment 
effects vary among blocks. Replication within blocks might be specifically 
of interest for late- phase studies, in which we do not want to get only 
a general­proof­of­concept­but­in­which­we­also­want­to­gain­insights­
into the­different­sources­of­variation­and­their­magnitude.­Replication­
within blocks is much less effective in increasing the power to detect 
context- independent effects (main effects) than use of additional blocks, 
but it is required to test for interactions between the factors of interest 
and the­context­factors.
Although the RCB design is a highly efficient means of combining 
rigorous standardization with heterogenization, it requires that blocks 
are sufficiently­large­to­include­at­least­one­replicate­of­each­treatment.­
When this cannot be done for technical reasons or when a larger number 
of blocking factors are considered, incomplete block designs139 are 
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standardization is culturally embedded 
in our community as the norm and best 
practice. It is done without questioning its 
validity. Consequently, more advocacy will 
be needed to convey the Janus- faced nature 
of standardization to the wider research 
community. One roadblock is conflicting 
evidence from other scientific disciplines 
such as physics, in which standardization 
is indeed an effective measure to reduce 
measurement error of technical replicates 
and, hence, to improve both the internal 
and the external validity of study results. 
However, heterogenization is commonly 
accepted practice in many other biological 
disciplines, particularly those dealing with 
whole organisms, including quantitative 
genetics, animal and plant breeding, ecology 
and evolutionary biology. To overcome 
this resistance, we need to challenge the 
underlying beliefs that standardization is 
best practice and to promote awareness 
that biological variation of the phenotype 
differs fundamentally from random noise 
(as exemplified in Box 1).
The designs recommended here intro uce 
challenges through changes in the way 
we practically run the experiments and 
analyse the data. A significant blocker for 
our community to embrace such changes 
is the current norm to publish studies 
with a narrow inference space with no 
acknowledgement of the limitations of 
the study findings. This approach has a 
significant impact on our research culture, as 
we are rewarded for publications regardless 
of the robustness of our findings. A further 
obstacle to change is the argument that 
heterogenization increases the complexity of 
the experiment and, thereby, complicates the 
analysis and increases the required sample 
size and economic costs of the experiment. 
Although it is true that heterogenized study 
designs are more complex, this does not 
hinder analysis, because statistical tools to 
deal with the added complexity are readily 
available (see Box 3). Here, scientists might 
need more encouragement to engage with 
those statistical concepts and apply them in 
their research practices85.
Despite a general understanding of the 
problem, researchers who wish to implement 
heterogenization face several unknowns. 
Which factors will have the strongest effects 
on the overall variation? How strong will 
the effects be? Within which range should 
we vary environmental factors? How 
different should the experiments be to be 
considered independent replicates? When 
does this require replication in a different 
laboratory, and when are sequential batches 
within the same laboratory sufficient? 
For some well- researched treatments or 
compounds we might have information 
about the effect of some of the more 
common heterogenization factors such 
as sex or strain, but in most cases we will 
lack this information and cannot answer 
those questions upfront. Some answers 
can be gleaned from the literature on the 
evolutionary biology and ecology of related 
animals, which provides a rich source of 
information on phenotypic and genetic 
heterogeneity. Educated guesses and rules 
of thumb for certain groups of interventions 
might give some guidance, but in the end 
we have to accept intrinsic uncertainties 
that can be resolved only empirically. 
Further research is therefore essential to 
explore these issues and provide guidance 
to the community in practical steps that can 
be taken.
Given the uncertainties with regard to 
heterogenization factors that will prove 
effective for any specific treatment, we 
do not think that the way forward should 
be a list of compulsory factors to be 
heterogenized in every study. Instead, we 
Biological variation
The variation of phenotypes in a population of 
organisms. it is the result of genetic variation, 
environmental influences on the organism and  
gene × environment interactions.
Confirmatory studies
studies designed to test specific hypotheses about  
the existence of a relationship or effect, its direction  
and magnitude using inferential statistical methods.  
The hypotheses are based on previous knowledge  
of the study system.
Exploratory studies
studies designed to probe for relationships or treatment 
effects of novel interventions without specific hypotheses 
about the direction and size of effects. The outcome of 
an exploratory study is a descriptive account of the 
observed effects.
External validity
The extent to which findings can be generalized to the 
desired inference space of animals (including humans) 
and/or other environmental conditions.
Gene × environment interactions
These subsume the non- additive joint effect of genetic 
and environmental influences on the development of the 
phenotype. As a consequence, environmental influences 
can have different effects on the phenotype depending 
on the organism’s genotype or genes can have differential 
effects depending on features of the environment.
Genotypes
organisms’ hereditary information as encoded in the 
genome.
Heterogenization
The deliberate augmentation of systematic or random 
biological variation in the study population.
Inference space
The range of organisms and environmental contexts for 
which the inference of an experiment is valid.
Internal validity
Refers to whether the effects observed in a study are 
due to manipulation of the independent variables and 
not some other, unknown factors.
Norm of reaction
A property of a genotype describing how an 
environmental factor affects the development of the 
phenotype. it can be conceptualized as a function 
mapping expected phenotypic trait values onto 
environmental parameter values.
Phenotype
The sum of an organism’s observable characteristics  
or traits, including its morphological, biochemical and 
physiological processes, behaviour and responses to 
external stimulation and treatments.
Phenotypic plasticity
The extent to which an organism changes its phenotype 
in response to environmental influences.
Random noise
Also known as measurement error, refers to unexplained 
variability in the data. it affects the variation but not the 
size of an experimental treatment effect.
Reproducibility
The ability to produce similar results by an independent 
replicate experiment using the same methodology in 
the same or a different laboratory.
Robustness
The ability of an organism to maintain a functioning 
phenotype under varying environmental conditions.  
it also refers to the stability of a response to an 
experimental treatment in the face of variation in 
environmental conditions.
3Rs principles
The guiding principles for a responsible approach to 
experimental animal research. They imply that a study 
involving the use of animals should be conducted only  
if the intended outcome cannot be achieved by use of 
no or non- sentient animals (replace), fewer animals 
(reduce) or procedures that are less harmful or improve 
animal well- being (refine).
Scientific rigour
As defined by the Us National institutes of Health, this 
means “the strict application of the scientific method  
to ensure robust and unbiased experimental design, 
methodology, analysis, interpretation and reporting  
of results. This includes full transparency in reporting 
experimental details so that others may reproduce  
and extend the findings”.
Standardization
The practice of minimizing both technical and biological 
variation in the study outcomes by identifying and 
controlling sources of variation that are believed to  
be putative confounders. standardization can aim  
at aspects of the environment in which a study is 
conducted (environmental standardization), aspects  
of the study subjects (phenotype standardization) or 
aspects of how procedures and interventions are 
conducted and how measurements are taken 
(operational standardization).
Glossary
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recommend that heterogenization of sex, 
genotype, age and environmental conditions 
should be recommended in general terms 
and that experimenters should be asked 
to discuss their choice of heterogenization 
measures — or the lack of such measures — 
with respect to the intended inference space.
Overcoming the reproducibility crisis. 
Besides counteracting factors inhibiting 
change, there is also a need to strengthen 
those factors motivating and driving 
change. Arguably the most compelling one 
is the reproducibility crisis in biomedical 
research. Reports pointing out issues with 
reproducibility have accumulated over 
the years, and the desire to solve this crisis 
should be a very strong motivation for 
driving change. Improving reproducibility 
can reduce long- term research costs, 
increase efficiency of drug development 
and reduce suffering of animals used for 
inconclusive research.
Connected to poor reproducibility, there 
is a related and very compelling issue: it is 
the reputation of research itself — and of 
animal research in particular — that is at 
stake4,86. The public funds research on the 
principal understanding that researchers 
use funding resources judiciously and 
efficiently. If the research community fails 
to resolve the current reproducibility crisis, 
then the public might legitimately question 
whether researchers adhere to this societal 
contract and whether investment in this 
kind of research should continue. Along 
the same lines, the right to use animals for 
research that might inflict pain and suffering 
on the animals is a privilege granted to 
researchers by society on the understanding 
that their research benefits humanity 
and that researchers use the animal resources 
responsibly, avoiding unnecessary harm and 
suffering. Again, a failure of the scientific 
community to resolve the current crisis 
might instigate a discussion as to whether 
this privilege should be revoked. Here, we 
believe that it is important to communicate 
that ignoring or denying the existence of 
a major reproducibility problem is not a 
solution and that only an honest and serious 
attempt by the entire scientific community 
to solve this problem can secure continued 
trust in science by the general public.
With respect to sample size, recent 
studies indicated that heterogenization can 
be introduced without a need to increase 
the overall sample size53,67,87. Larger sample 
sizes are needed only when multiple 
factors are heterogenized; however, the 
increase in economic and ethical costs 
of larger experiments should be more 
than outweighed in the long run, as fewer 
follow- up studies will be required and 
fewer dead ends will be pursued. Promises 
for long- term benefits are, by their very 
nature, vague, which means that they are 
rather weak arguments for implementing 
change. However, if the focus is shifted 
from the costs of an individual study (both 
financial and ethical in terms of the numbers 
of animals used) to the amount of knowledge 
gained per study or per animal (Box 5), 
then it becomes immediately apparent that 
heterogenized studies can deliver a better 
benefit–cost ratio than narrowly standardized 
studies. This change of focus from the 
number of animals within single experiments 
to the value delivered by these experiments 
is also reflected in the recent change in the 
definition of ‘reduction’ by the UK National 
Centre for the Replacement, Refinement and 
Reduction of Animals in Research (NC3Rs), 
which now includes “experiments that are 
robust, reproducible and truly add to the 
knowledge base”88. Researchers, regulators, 
funders and editors need to understand 
that studies allowing inferences about both 
sexes, genetically diverse populations or a 
variety of environmental conditions will add 
more richly to the knowledge base, and that 
standardization of animal subjects inevitably 
reduces the inference space. A promising 
way forward might be insistence by editors, 
reviewers and funders that authors have to 
specify the inference space of their studies; 
that is, the population — and the biological 
variation within that population — about 
which they will be able to draw inferences. 
Some funders are already requiring some 
forms of heterogenization (Box 2 and Box 3). 
For example, both the US National Institutes 
of Health89 and the Organisation for 
Economic Co- operation and Development90 
recommend that studies in preclinical 
biomedical research should comprise 
both sexes, and the European Medicines 
Agency requires that animal toxicity tests 
for compounds have to be done in at least 
two different species before translation 
to humans91. We therefore propose that 
reporting guidelines (for example, the 
ARRIVE guidelines92 and Nature Research’s 
Reporting Summary93) request that 
experimenters explicitly state the intended 
inference space and discuss their results with 
respect to the measures taken (for example, 
the factors that were heterogenized) to cover 
that inference space.
Conclusions
Accumulating evidence of poor 
reproducibility of research has stimulated 
heated debate about possible causes and 
remedies of irreproducibility leading to the 
so- called reproducibility crisis. Suggested 
causes of poor reproducibility include lack 
of scientific rigour, low statistical power, 
publication bias, analytical flexibility (for 
example, P- hacking), pseudoreplication 
and outright fraud6,12,94–96. These causes are 
all thought to be promoted by a system that 
rewards novel and spectacular findings 
— even if they are spurious — more than 
robust, reproducible evidence97. However, 
we contend that this list is incomplete for 
research involving living organisms as an 
important source of replication failure 
has been ignored: standardization of the 
animals, leading to unrealistically low 
estimates of biological variation and, as a 
consequence, to study- specific, idiosyncratic 
results. As biological variation differs from 
random noise and variation of technical 
replicates — as clearly demonstrated 
by the reaction norm framework — its 
removal through standardization generates 
overconfident and biased estimates. Here we 
have outlined the rationale for our claim, as 
well as its scientific, ethical and economic 
implications, and presented targeted 
scenarios for improvement. We maintain 
that unless researchers take the context 
dependency of their animals’ treatment 
responses into account, reproducibility of 
animal research will remain limited despite 
efforts to avoid other causes that affect 
reproducibility. We call on the community 
(researchers, publishers, policymakers, 
professional bodies, funders and so on) to 
engage and explore how they can support 
the paradigm shift that is needed to deliver 
robust research.
Box 5 | Forces impacting change
Forces driving change 
•­Reproducibility crisis
•­ethical focus on knowledge gain per animal




•­Scientific reward system favouring single 
small- scale studies
•­ethical focus on the number of animals 
per study
•­Belief in the value of standardization
•­Cost per experiment
•­Complexity of design and analysis
•­Research culture (common sense of best 
practice)
•­unknown solution (how to implement 
heterogenization)
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